依折麦布和辛伐他汀联合应用对急性冠脉综合征患者血脂达标率的影响研究

目的 研究依折麦布联合辛伐他汀对急性冠脉综合征(ACS)患者血脂达标率的影响.方法 入选初次就诊诊断的ACS患者80例,随机分为2组,各40例.辛伐他汀组给予辛伐他汀(40mg/d)治疗,联合组给予辛托伐他汀(40mg/d)和依折麦布(10mg/d)联合治疗,6周后比较两组患者血脂达标率及不良反应.结果 与治疗前相比,两组的总胆固醇、高密度脂蛋白胆固醇(HDL-C)、低密度脂蛋白胆固醇(LDL-C)、三酰甘油水平均有明显降低;与治疗前比较,联合组的HDL-C水平上升,差异无统计学;LDL-C的调脂幅度和LDL-C的达标率均高于辛伐他汀组.联合组不良反应发生率与辛伐他汀组比较,差异无统计学意义(P＞0.05).结论 依折麦布联合辛伐他汀可以有效治疗ACS患者的血脂,并提高其达标率,优于单用辛伐他汀.依折麦布联合辛伐他汀联合可应用于ACS的初始降脂治疗.

The Systematic Rate Research of Ezetimibe Combination with Simvastatin on Blood Lipids in Patients with Acute Coronary Syndrome

Objective To research the systematic rate of ezetimibe combined with simvastatin on blood lipids in patients with acute coronary syndrome(ACS).Methods All the ACS patients were diagnosis first,80 cases were randomly divided into two groups,one group given simvastatin(40mg/d),another group given simvastatin(40mg/d) and ezetimibe(10mg/d) combination,blood lipids compliance rate and adverse reactions incidencewere compared after 6 weeks.Results Compared with before the treatment,the two groups in total cholesterol,LDL,triglyceride levels were significantly reduced;compared with before the treatment of HDL-C level of the joint group increased,but no significant difference;LDL-compliance rates of the lipid was higher than simvastatin group.The incidence of adverse reactions of the combined group was no significant differencecompared with the simvastatin group.Conclusion ezetimibe combined with simvastatin can increase the compliance rate of serum lipids in patients with ACS,better than simvastatin,and security;ezetimibecombined with simvastatin can be applied to the initial lipid-lowering therapy in ACS.